What We Measure, and When It Publishes
What MindScape Retreat's stimulant addiction protocol measures, and when the numbers publish. Cocaine, methamphetamine, and amphetamine use disorders are scored on validated craving and anhedonia instruments from baseline through 90-day follow-up.
Cocaine and methamphetamine dependence are driven by a fundamentally different neurobiological substrate than opioid addiction. Where opioids hijack the mu-opioid receptor system, stimulants operate primarily through catastrophic dysregulation of dopaminergic pathways, overwhelming the nucleus accumbens, stripping dopamine transporter density, and progressively dismantling the prefrontal regulatory circuits that enable voluntary control over drug-seeking behavior. This distinction explains why no pharmacotherapy has been approved for stimulant use disorder: there is no clean molecular target analogous to methadone's mu-opioid receptor agonism or buprenorphine's partial agonism.
Ibogaine's documented capacity to upregulate glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area and nucleus accumbens positions it uniquely among investigational treatments for stimulant addiction. GDNF is the primary neurotrophic factor governing dopaminergic neuron survival and plasticity; its upregulation directly counters the receptor downregulation and transporter depletion that chronic stimulant exposure produces. This mechanism, absent in any approved pharmacotherapy, is central to the clinical rationale for ibogaine treatment in this population.
Study Overview
Clinical Observations Across Stimulant Use Disorders
Stimulant addiction, encompassing cocaine, methamphetamine, and amphetamine use disorders, presents a distinct clinical challenge that separates it from opioid or alcohol dependence. There is no significant physical withdrawal syndrome to manage; what drives continued stimulant use and relapse is intense psychological craving, anhedonia, and profound dysregulation of the brain's dopamine reward circuitry. Standard addiction medicine has no approved pharmacotherapy for stimulant use disorder, leaving behavioral interventions as the primary treatment modality, with limited efficacy in moderate-to-severe presentations.
MindScape Retreat's stimulant protocol targets those core neurobiological drivers through mechanisms unavailable to behavioral therapy alone, and it measures the result rather than asserting it. Craving intensity is tracked using the Cocaine Selective Severity Assessment (CSSA), the Amphetamine Selective Severity Assessment (ASSA), and a visual analog scale (VAS) for subjective craving. Anhedonia, the inability to experience pleasure, which drives relapse as patients chase a pharmacologically depleted reward system, is assessed using a validated composite scale.
Guests who reach us for stimulant dependency have typically been using for years and have already made several serious quit attempts. Poly-substance patterns are common, most often concurrent alcohol use disorder, and that is incorporated into protocol design rather than treated as a disqualifier. Structured outcome collection in this program began in July 2026; cohort aggregates publish at mindscaperetreat.com/outcomes once at least 20 people hold paired baseline and follow-up data, never before.
Measuring stimulant craving presents a methodological challenge absent from opioid treatment research. There is no stimulant equivalent of the Clinical Opiate Withdrawal Scale (COWS) because stimulant cessation does not produce a defined autonomic withdrawal syndrome: no diaphoresis, piloerection, or measurable physiological cascade to score. What stimulant-dependent patients experience is a psychological crash: anhedonia, dysphoria, intense drug craving, and cognitive impairment driven entirely by dopamine depletion rather than receptor hypersensitivity. The protocol therefore scores craving on the Cocaine Selective Severity Assessment (CSSA) and a 0 to 100 Visual Analog Scale for subjective craving, alongside a validated anhedonia composite that directly indexes the reward capacity deficit underlying stimulant dependence.
The anhedonia measure deserves particular clinical weight. Anhedonia, the inability to experience pleasure from normally rewarding activities, is not a secondary symptom of stimulant addiction; it is the primary neurobiological driver of relapse. Patients return to cocaine or methamphetamine not purely for euphoria but because their dopamine system has been so thoroughly depleted that no natural reward registers. Any intervention that meaningfully improves anhedonia is addressing the root mechanism of stimulant relapse risk.
Craving and anhedonia are scored because they are the two measures that track ibogaine's proposed action on dopaminergic function at the receptor and transporter level. In neuroimaging studies of chronic stimulant users, DAT density in the striatum is markedly reduced relative to non-using controls, a direct correlate of anhedonia severity and craving intensity. Ibogaine's induction of GDNF expression in the VTA drives dopaminergic axon remodeling and DAT re-expression, which is the receptor-level reset these instruments are positioned to detect.
Anhedonia and craving are expected to move on different clocks, which is why both are scored at 30, 60, and 90 days rather than once at discharge. D1 and D2 receptor resensitization and full DAT re-expression require weeks of continued neuroplastic remodeling beyond the acute ibogaine pharmacological window, so the reward system is still rebuilding long after the acute phase ends. The implication for clinical management is direct: integration support and relapse prevention work are most critical during precisely that period, when the neurochemical recovery is still actively unfolding.
Mechanism of Action
Dopamine Transporter Upregulation and Prefrontal Circuit Restoration
Chronic stimulant use produces predictable and well-characterized neurobiological damage to the dopaminergic system. Repeated cocaine and methamphetamine exposure downregulates dopamine transporter (DAT) expression, desensitizes D1 and D2 receptor populations in the nucleus accumbens and striatum, and progressively weakens top-down regulatory control from the prefrontal cortex over limbic reward circuitry. The result is a brain state in which natural rewards generate minimal pleasure, stimulant craving is overwhelming, and the cognitive capacity to resist compulsive use is structurally impaired.
Ibogaine addresses this damage through several convergent mechanisms. DAT upregulation, among ibogaine's most documented neurochemical actions, directly restores dopamine transporter density toward pre-addiction levels, normalizing synaptic dopamine clearance and reducing the hyperdopaminergic surges that perpetuate compulsive use. Concurrent D1 and D2 receptor sensitization reset reduces the tolerance-driven need for escalating stimulant doses to achieve any reward state.
Critically, ibogaine's sigma-1 receptor agonism and NMDA receptor modulation support restoration of prefrontal cortex-to-striatal circuit connectivity, the neurological infrastructure of impulse control and delayed gratification. This prefrontal restoration component differentiates ibogaine from purely dopaminergic interventions, and it is why the protocol aims at the circuitry behind compulsive use rather than at craving suppression alone.
The mechanism of action discussion above describes ibogaine's pharmacological effects on the dopaminergic system as a unified process. In clinical practice, the application of those mechanisms differs meaningfully depending on the specific stimulant involved and the patient's broader substance use history. Cocaine's short-acting, predominantly DAT-blocking profile and methamphetamine's longer-acting, vesicular monoamine transporter 2 (VMAT2)-disrupting neurotoxicity create distinct neurobiological presentations that require individualized protocol design, particularly around pre-treatment abstinence timing, dosing strategy, and the intensity of post-treatment integration support.
Clinical Considerations
Cocaine vs. Methamphetamine: Differences That Inform Protocol Design
While cocaine and methamphetamine share a core mechanism of dopaminergic dysregulation, their pharmacological profiles and clinical presentations differ in ways that inform ibogaine protocol design. Cocaine's shorter half-life and predominant DAT-blocking mechanism produce a more acute, episodic reward cycle; methamphetamine's longer duration of action, VMAT2 disruption, and greater neurotoxic potential to dopaminergic terminals produce more severe and longer-lasting anhedonia. Methamphetamine-dependent patients typically present with more profound baseline anhedonia and require more intensive integration support in the weeks following ibogaine treatment.
Amphetamine use disorder, including prescription stimulant dependence originating from ADHD treatment misuse, presents a third clinical profile characterized by mixed reward-seeking and functional-performance motivation. Many amphetamine-dependent patients have significant anxiety and cognitive concerns about functioning without stimulants; the integration protocol specifically addresses this through structured cognitive reframing and, where appropriate, referral to non-stimulant ADHD management.
Poly-substance presentation is common in this population. A substantial proportion of stimulant-dependent patients also meet criteria for alcohol use disorder; many use cannabis to manage stimulant-induced anxiety; some have concurrent benzodiazepine dependence. Each poly-substance profile is assessed individually. Patients with active benzodiazepine dependence are not required to taper at home. The benzodiazepine taper is performed onsite at MindScape under continuous physician supervision and telemetry, with twice-daily ibogaine TA (total alkaloid) booster doses bridging GABAergic tone during washout. Patients arrive on their current prescribed dose; the HCl flood dose is administered only after the benzodiazepine has been titrated to a protocol-defined safe threshold and the seizure-risk window has cleared. Alcohol use disorder, when present, is incorporated into the treatment framing and integration planning rather than treated as a disqualifying factor.
Clinical Protocol
10 to 12 Day Stimulant Treatment Protocol
Comprehensive Addiction & Psychiatric Assessment
Every stimulant-dependent candidate completes a structured intake assessment covering substance use history (type, duration, quantity, route of administration), prior treatment attempts, co-occurring psychiatric diagnoses, and current poly-substance use. CSSA or ASSA craving scales are administered at baseline. Patients with co-occurring depression, anxiety, or ADHD receive additional psychiatric evaluation, as these conditions directly influence protocol design and integration planning. Medical history, including cardiac history, is reviewed in detail.
Cardiac Screening & Medical Clearance
Full bloodwork, EKG with QTc measurement, and cardiovascular evaluation are mandatory for all stimulant-dependent candidates. Chronic cocaine use carries a documented risk of subclinical cardiac structural changes and elevated arrhythmia susceptibility; methamphetamine use is associated with cardiomyopathy in long-term users. These risks make cardiac clearance more than a routine formality in this population. Patients with significant findings, prolonged QTc, structural abnormality, or active cardiac symptoms, are not accepted until those findings are addressed and cleared by a cardiologist.
Stimulant Abstinence & Preparation Period
A mandatory stimulant abstinence period is required prior to ibogaine administration, typically a minimum of five to seven days for cocaine and five to ten days for methamphetamine, depending on use pattern. This abstinence period reduces the acute pharmacological load on the dopaminergic system and allows initial normalization of sleep, appetite, and cardiovascular parameters. Patients with concurrent benzodiazepine dependence arrive on their current prescribed dose and undergo a structured onsite taper during this preparation phase under continuous physician supervision, supported by twice-daily ibogaine TA booster bridging. Pre-arrival benzodiazepine tapering is not required. Nutritional repletion, hydration, and sleep hygiene support are provided throughout preparation.
Ibogaine Treatment at MindScape Retreat, Cozumel
Ibogaine is administered under continuous physician and nursing supervision in our medically equipped retreat facility on Cozumel Island. Stimulant-dependent patients receive an individualized dosing protocol designed by our medical director, accounting for substance type, duration of use, degree of dopaminergic depletion, body composition, and poly-substance history. Cardiac monitoring is continuous throughout the treatment session. The active treatment experience typically lasts 12 to 24 hours, followed by a structured medical recovery period before patients enter the integration phase.
Integration Therapy & Relapse Prevention Planning
Integration for stimulant-dependent patients specifically targets the anhedonia and identity dimensions of stimulant addiction that are most predictive of relapse. Many patients have organized significant portions of their social, professional, and recreational lives around stimulant use; the integration process includes structured work on building a reward landscape that does not depend on pharmacological dopamine augmentation. A written relapse prevention plan, referrals to ongoing outpatient support, and scheduled check-in calls at 30, 60, and 90 days post-treatment are included for every patient.
Frequently Asked Questions
Questions About Ibogaine for Stimulant Addiction
Every MindScape treatment program includes a guided 5-MeO-DMT (Bufo) ceremony, part of the all-inclusive price, not an add-on.